Relmada Therapeutics, Inc. (NASDAQ: RLMD) has caught investors’ attention following a recent rating upgrade to “Outperform” from Andrew Berens at Leerink Partners. This upgrade, issued on January 23, 2026, comes with a price target of $8, suggesting notable upside potential from the current trading price of $3.90. As the market reevaluates the company’s potential, this report provides an essential overview for investors navigating these developments.
Recent Price Action
In the wake of the rating change, Relmada’s stock price of $3.90 reflects a marginal decline of 1.51% or $0.06. The stock has experienced significant price fluctuations lately, with a yearly high of $1522.30—though it is crucial to note that this peak is not necessarily indicative of current performance, given recent pressures. The week 52 high stands at a comparatively restrained -23.83, while the stock’s volume clocked in at 906,880 shares, below its average volume of 1,201,480. With a market capitalization of approximately $286 million and a beta of 0.775, RLMD generally demonstrates lower volatility compared to the broader market, although the recent week saw a volatility measure of 7.75%, indicating notable uncertainty in the short term.
[chart type=’price’ value=’RLMD’]
Short- and Long-Term Performance
Delving into Relmada’s historical performance reveals a mixed bag across different time frames. Over the past 30 days, the stock has dropped by 1.75%, indicating some short-term weakness. However, the quarterly performance tells a different story, surging by a remarkable 96.02%. This reflects a strong recovery or positive momentum resulting from possibly favorable market conditions or company-specific news. On an even larger scale, the past year has witnessed an astounding yearly return of 936.57%, underscoring a dramatic turnaround that may intrigue both potential and existing investors. Yet, the market’s recent volatility, with 30-day volatility at around 7.88%, continues to suggest that investors should approach with caution amid the relatively tumultuous trading environment.
[chart type=’performance’ value=’RLMD’]
Earnings Analysis
In terms of earnings performance, Relmada recently reported an EPS of -$0.30404, significantly missing analysts’ expectations of -$0.04. This translates to a surprising 660.1% earnings surprise, which can often signal potential issues with operational efficiency or revenue generation. Looking back to August 2025, the company’s EPS was reported at -$0.30, slightly under the estimated -$0.25, indicative of a lack of upward momentum in earnings forecasts. This pattern raises questions about the quality and predictability of earnings, elements that are critical for long-term investment decisions.
[chart type=’income-bar-chart’ value=’RLMD’]
Analyst / Consensus View
The consensus around Relmada Therapeutics, represented in the most recent analyst ratings, echoes a bullish sentiment. With total ratings of 3, all three analysts have issued a “Buy” rating, translating to a strong positive posture with no holds or sells noted. The average price target from these analysts stands at $9, with a high of $10 and a low of $8. Given the current price of $3.90, this represents a potential upside that could be appealing to growth-focused investors searching for emerging opportunities.
[chart type=’analyst-ratings’ value=’RLMD’]
Stock Grading or Fundamental View
Relmada Therapeutics holds a Stocks Telegraph grading score of 47. This score reflects an analysis of the company’s overall financial health and market position, hinting at the potential for underlying weaknesses despite recent momentum. While the stock’s performance has been impressive over the past year, this grading suggests that further scrutiny may be warranted. Whether driven by innovative products or strategic partnerships, Relmada’s path forward must be navigated carefully, especially as it seeks to convert its recent high-volatility performance into sustainable growth.
[chart type=’st-cards’ value=’RLMD’]
Conclusion
For investors contemplating an entry into Relmada Therapeutics, the stock may particularly appeal to those with a higher risk tolerance who are looking for long-term growth potential. While the recent upgrade from Leerink Partners provides a positive outlook, the significant EPS miss and striking volatility present inherent risks. Careful consideration of these factors is essential for informed investment decisions. As the market continues to digest the implications of the latest ratings and performance metrics, RLMD remains a stock worth monitoring closely for any shifts in dynamics that could affect its trajectory.